Taimur Akram, | |
90 Shenango St, Greenville, PA 16125-2060 | |
(724) 588-4240 | |
Not Available |
Full Name | Taimur Akram |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 15 Years |
Location | 90 Shenango St, Greenville, Pennsylvania |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902034804 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | OS017199 (Pennsylvania) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Upmc Horizon | Greenville, PA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Upmc Community Medicine Inc | 2062318975 | 690 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
Health care professionals preparing patients for operations will soon be able to use award-winning on-line learning material prepared at the Health Care Innovation Unit at the University of Southampton.
A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.
Using a small noncoding RNA, microRNA 211, and tools that track the stability and decay of the protein-coding and noncoding RNAs in lab-grown melanoma cells, a team led by a Johns Hopkins Kimmel Cancer Center researcher identified highly unstable RNA molecules in human melanomas, including a novel miR-211 target gene DUSP3.
› Verified 1 days ago
Entity Name | Upmc Community Medicine Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1558976092 PECOS PAC ID: 2062318975 Enrollment ID: O20040217000388 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
Health care professionals preparing patients for operations will soon be able to use award-winning on-line learning material prepared at the Health Care Innovation Unit at the University of Southampton.
A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.
Using a small noncoding RNA, microRNA 211, and tools that track the stability and decay of the protein-coding and noncoding RNAs in lab-grown melanoma cells, a team led by a Johns Hopkins Kimmel Cancer Center researcher identified highly unstable RNA molecules in human melanomas, including a novel miR-211 target gene DUSP3.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Taimur Akram, 90 Shenango St, Greenville, PA 16125-2060 Ph: () - | Taimur Akram, 90 Shenango St, Greenville, PA 16125-2060 Ph: (724) 588-4240 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
Health care professionals preparing patients for operations will soon be able to use award-winning on-line learning material prepared at the Health Care Innovation Unit at the University of Southampton.
A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.
Using a small noncoding RNA, microRNA 211, and tools that track the stability and decay of the protein-coding and noncoding RNAs in lab-grown melanoma cells, a team led by a Johns Hopkins Kimmel Cancer Center researcher identified highly unstable RNA molecules in human melanomas, including a novel miR-211 target gene DUSP3.
› Verified 1 days ago
James L Liszewski, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 Fax: 724-588-1820 | |
Christina Wong, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 | |
Dr. Jeremy James Mashburn, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 348 Main St, Greenville, PA 16125 Phone: 724-588-5250 Fax: 724-588-5253 | |
Dr. Briana D. Yee-providence, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 90 Shenango Street, Greenville, PA 16125 Phone: 724-588-4240 Fax: 724-588-1820 | |
Laura B Yohe, CRNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 90 Shenango St, Suite 12, Greenville, PA 16125 Phone: 724-589-0290 Fax: 724-589-0293 | |
Alicia Baker, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 | |
Dr. George F Reeher, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 90 Shenango St, Greenville, PA 16125 Phone: 724-588-4240 Fax: 724-588-0198 |